摘要
目的观察贝伐单抗联合化疗对结直肠癌患者肿瘤组织内的肿瘤相关巨噬细胞(TAMs)水平及微血管密度(MVD)的影响。方法入选100例结直肠癌患者,随机分为观察组(60例)和对照组(40例),观察组在对照组常规化疗基础上加用贝伐单抗治疗。化疗2~4个月后行外科手术治疗。另选10例良性结直肠病变者作为正常组。RTPCR法测定TAMs标记物CD68mRNA的表达水平,免疫组织化学法检测标本MVD分布。结果观察组与对照组患者肿瘤组织中TAMs标记的CD68mRNA表达水平分别为(1.46±0.47)及(1.92±0.51),均高于正常结直肠组织的表达量(0.11±0.04),差异有显著性(P>0.05);两组肿瘤内MVD分布分别55±12和48±10,均高于正常结直肠组织(26±8),差异有显著性(P<0.01)。经贝伐单抗联合化疗后观察组患者肿瘤组织中CD68mRNA及MVD低于常规化疗的对照组(1.46±0.47 vs.1.92±0.51,48±10 vs.55±12,P<0.05);TAMs计数与MVD存在正相关(r=0.331,P=0.034)。结论贝伐单抗联合化疗可通过阻断肿瘤内微血管形成及局部炎症反应等途径抑制肿瘤生长和转移,MVD可作为一个可靠的标记物预测贝伐单抗的疗效。
Objective To observe the effect of Bevacizumab with chemotherapy on the levels of tumor-associated macrophage （TAMs） and microvessel density （MVD） in cancerous tissue for patients with colorectal cancer.Methods One hundred patients with colorectal cancer were randomly divided into the control group （40 cases） and the observation group （60 cases）.Both of them were treated with conventional chemotherapy,on the basis of it the observation group were treated with Bevacizumab every 2 weeks for a treated cycle.Another group including 10 cases of benign colorectal lesions was as normal group.Results The TAMs level was （1.46＆#177;0.47） and （1.92＆#177;0.51） in colorectal cancer of control group and observation group,respectively,and variance of MVD in two groups was markedly higher than that of the normal group.There were significant differences （1.46＆#177;0.47 vs.1.92＆#177;0.51,48＆#177;10 vs.55＆#177;12,P＆lt;0.01）.In addition,the distribution of MVD in the two groups was （55＆#177;12） and （48＆#177;10）,respectively,which were higher than those in normal colorectal tissues （26＆#177;8）,there were markedly differences （P＆lt;0.01）.There was a positive relationship among TAMs and MVD （r=0.331,P=0.034）.Conclusion Bevacizumab combined with chemotherapy can suppress tumor growth and metastasis by blocking angiogenesis within the tumor and local inflammatory reaction pathways,MVD can be used as a reliable marker to predict the efficacy of bevacizumab.
出处
《临床和实验医学杂志》
2017年第13期1297-1299,共3页
Journal of Clinical and Experimental Medicine
基金
沧州市科技计划项目(编号:131302114)
关键词
结直肠癌
贝伐单抗
肿瘤相关巨噬细胞
微血管密度
Colorectal cancer
Bevacizumab
Tumor-associated macrophage
Microvessel density
